Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Sputnik V

Sputnik V

The world's first registered vaccine based on a well-studied human adenovirus vector platform


Sputnik V is the world's first registered vaccine based on a well-studied human adenovirus vector platform. It has been approved for usage in 71 countries with a total population of 4 billion people.

The vaccine name comes after the first Soviet space satellite. The launch of Sputnik-1 in 1957 reinvigorated space research around the world, creating a so called “Sputnik moment” for the global community.

The vaccine’s efficacy is 97.6%, based on the analysis of data on the incidence of coronavirus among Russians vaccinated with both vaccine components between December 5, 2020 and March 31, 2021.

Phase 1 and 2 clinical trials for the vaccine were completed on August 1, 2020. The Phase 3 clinical trial results were published in Russia in the Lancet magazine on February 2, 2021. Phase 3 clinical trials of Sputnik V have also been successful in the UAE, India, Venezuela and Belarus.

The Sputnik V vaccine is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have plagued humanity for millennia.

Sputnik V was the first coronavirus vaccine to use a heterogeneous boosting approach based on 2 different vectors for 2 vaccine shots. This approach generates a more sustainable immunity compared to vaccines that use the same delivery mechanism for both shots.

The safety, efficacy and lack of long-term adverse effects of adenovirus vaccines have been proven in more than 250 clinical trials over two decades.

Sputnik V does not cause severe allergies.


August 2020
Phases I and II of two clinical trials were completed.
May 2020

The Gamaleya Research Institute of Epidemiology and Microbiology announced that it had developed the vaccine without serious side effects.

Further reading


Documentaries, videos and podcasts

Golden logo
By using this site, you agree to our Terms & Conditions.